Browse drugs

…Introduction Nintedanib and pirfenidone reduce the rate of progression in fibrotic lung…

…one had a significantly higher discontinuation risk compared to nintedanib (HR 1.60, 95% CI 1.05–2.44, p=0.029).121 patients (44%) died be…

…rotic eligibility, particularly reducing the proportion meeting pirfenidone thresholds. In contrast, GLI-2022 has minimal impact on modelle…

… disease progression and improve long-term outcomes are needed. BMS-986353, a CD19-directed CAR T NEX-T cell therapy, showed early efficac…

… (SSc) patients. The recent ERS/EULAR guidelines recommend both mycophenolate mofetil (MMF) and rituximab (RTX) for SSc-ILD and suggest to use a comb…

…ostadil in 2013 and iloprost in 2016, both initially effective. Iloprost was successfully re-administered in 2019 and 2024 but discontin…

… pneumonia (NSIP). Immunosuppressive therapy was initiated with mycophenolate mofetil, titrated to 1000 mg twice daily, alongside with nintedanib 100…

… (14.8%), nintedanib (11.3%), ibrutinib (10%), azacitidine, and bosentan (7.8%). OD distribution by ATC group was dominated by L (n=19),…

…ge of 74.5 years. The most frequently prescribed therapies were osimertinib (n=24), alectinib (n=9), and nintedanib (n=5). At baseline, 84%…

… (IPF). In the phase 2a study INTEGRIS-IPF study (NCT04396756), bexotegrast was well tolerated and showed antifibrotic activity.Methods and…

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…and hydroxyproline content levels in the PCLS model.Conclusions Treprostinil inhibits RhoA activation and this may be via PPARβδ activation.…